A nanocrystal-based formulation improves the pharmacokinetic performance and therapeutic response of albendazole in dogs

PAREDES, ALEJANDRO JAVIER; LITTERIO, NICOLÁS; DIB, ALICIA; ALLEMANDI, DANIEL ALBERTO; LANUSSE, CARLOS; BRUNI, SERGIO SÁNCHEZ; PALMA, SANTIAGO DANIEL

JOURNAL OF PHARMACY AND PHARMACOLOGY

PHARMACEUTICAL PRESS-ROYAL PHARMACEUTICAL SOC GREAT BRITIAN

Año: 2017

0022-3573

bjectives.Here, we aimed to assess the pharmacokinetic performance and therapeutic response (anthelmintic efficacy) of an albendazole (ABZ) nano-sized formulation in dogs.Methods.In the pharmacokinetic study, ABZ self-dispersible nanocrystals(SDNCS) and a control formulation were administered orally to healthy dogs(n = 6). The concentrations of the sulphoxide metabolite in plasma were determined by high-performance liquid chromatography. For the anthelmintic efficacy trial, SDNCS and a commercially available formulation of ABZ were givento naturally parasitised dogs. The number of Ancylostoma caninum eggs in thefaeces was determined using the McMaster technique.Key findings.The area under the curve, Tmax and Cmax for the SDNCS wereimproved compared to the control. The efficacy study showed no statistical differences between the SDNCS and the commercial formulation at the doses of 25and 12.5 mg/kg. However, significant differences (P < 0.05) between the treatments were found at 6.25 mg